References
- 1. Devic E. (1894) Myélite subaiguë compliquée de névrite optique. Bull. Med., 8: 1033–1034.
- 2. Gault F. (1894) De la neuromyélite optique aiguë. Thèse. In: Lyon, A. Rey.
- 3. Modi G., Mochan A., Modi M., Saffer D. (2001) Demyelinating disorder of the central nervous system occurring in black South Africans. J. Neurol. Neurosurg. Psychiatr., 70(4): 500–505.
- 4. Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, 364(9451): 2106–2112.
- 5. Lennon V.A., Kryzer T.J., Pittock S.J. et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Еxperiment. Med., 202(4): 473–477.
- 6. Saadoun S., Waters P., Bell B.A. et al. (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 133(2): 349–361.
- 7. Papadopoulos M.C., Verkman A. (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol., 11(6): 535–544.
- 8. Ratelade J., Zhang H., Saadoun S. et al. (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol., 123: 861–872.
- 9. Reindl M., Jarius S., Rostasy K., Berger T. (2017) Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr. Opin. Neurol., 30(3): 295–301.
- 10. Zamvil S.S., Slavin A.J. (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol. Neuroimmunol. Neuroinflamm., 2(1): e62.
- 11. Melamed E., Levy M., Waters P.J. et al. (2015) Update on biomarkers in neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm., 2(4).
- 12. Quarles R.H. (2002) Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell. Mol. Life Sci. CMLS, 59: 1851–1871.
- 13. Sharpe A.H., Freeman G.J. (2002) The B7–CD28 superfamily. Nat. Rev. Immunol., 2(2): 116–126.
- 14. Marignier R., Hacohen Y., Cobo-Calvo A. et al. (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol., 20(9): 762–772.
- 15. Uhlén M., Fagerberg L., Hallström B.M. et al. (2015) Tissue-based map of the human proteome. Science, 347(6220): 1260419.
- 16. Corbali O., Chitnis T. (2023) Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front. Neurol., 14: 1137998.
- 17. Takai Y., Misu T., Kaneko K. et al. (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain, 143(5): 1431–1446.
- 18. Bradl M., Reindl M., Lassmann H. (2018) Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr. Opin. Neurol., 31(3): 325.
- 19. Macrini C., Gerhards R., Winklmeier S. et al. (2021) Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain, 144(8): 2375–2389.
- 20. Sabatino Jr.J.J., Pröbstel A.K., Zamvil S.S. (2019) B cells in autoimmune and neurodegenerative central nervous system diseases. Nature Rev. Neurosci., 20(12): 728–745.
- 21. Wingerchuk D.M., Banwell B., Bennett J.L. et al. (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2): 177–189.
- 22. Banwell B., Bennett J.L., Marignier R. et al. (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol., 22(3): 268–282.